Tamoxifen Benefit Lasts 10 Years, New Data Show: The Relative Risk of Breast Cancer Was Reduced by a Highly Significant 29%, Compared with Placebo

By Jancin, Bruce | Clinical Psychiatry News, February 2007 | Go to article overview

Tamoxifen Benefit Lasts 10 Years, New Data Show: The Relative Risk of Breast Cancer Was Reduced by a Highly Significant 29%, Compared with Placebo


Jancin, Bruce, Clinical Psychiatry News


SAN ANTONIO -- A new 10-year follow-up from a landmark clinical trial of tamoxifen for breast cancer prevention indicates that the benefit continues strongly throughout the next half decade following completion of the standard 5 years of therapy, whereas adverse events are confined to the active treatment period.

"The risk-benefit ratio improves with longer follow-up. I think this is terribly important for the overall evaluation of tamoxifen in prevention. If you get the same benefit in the second 5 years as in the first 5 years without any of the side effects, the risk-benefit ratio is going to be at least twice as good as that currently computed based on just 5 years of data," Jack Cuzick, Ph.D., said at a breast cancer symposium sponsored by the Cancer Therapy and Research Center.

He presented a 10-year update from the first International Breast Cancer Prevention Study (IBIS-I), in which 7,154 women at high risk for breast cancer were randomized to 5 years of daily tamoxifen or placebo.

Such a placebo-controlled trial could not be undertaken today for ethical reasons because tamoxifen is now approved as a breast cancer chemopreventive agent; however, at 10 years the IBIS-I participants still remain blinded as to their treatment arm.

The primary end point was the incidence of breast cancer, which at 10 years was 3.9% in the tamoxifen arm and 5.5% with placebo, for a highly significant 29% relative risk reduction. This result included a 38% reduction in ductal carcinoma in situ and a 27% decrease in invasive breast cancers. There were 87 estrogen receptor-positive invasive breast cancers in the tamoxifen group and 129 in controls, for a 34% relative risk reduction. As expected, tamoxifen had no effect on the rate of estrogen receptor-negative tumors, said Dr. Cuzick, the IBIS-I chairman and head of the center for epidemiology, mathematics, and statistics at Cancer Research UK, London.

Tamoxifen prevented tumors of all grades. Importantly, the risk reduction was as great in year 10 as in year 1.

"This strong late reduction in cancers is very strong evidence that we're not only preventing the early cancers, which could to some extent be a matter of holding cancers in check, but we're actually preventing new tumors, and that this preventive effect is very, very long-term indeed," added Dr. Cuzick, who is also the John Snow Professor of Epidemiology at the Wolfson Institute of Preventive Medicine at Queen Mary's, University of London.

There was a strong, albeit nonsignificant, trend for a greater reduction in invasive breast cancers with tamoxifen in the 48% of subjects who were premenopausal at entry. …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Tamoxifen Benefit Lasts 10 Years, New Data Show: The Relative Risk of Breast Cancer Was Reduced by a Highly Significant 29%, Compared with Placebo
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.